Targeting TRAIL death receptors

Current Opinion in Pharmacology

Volumn 8, Issue 4, 2008, Pages 433-439

  Oldenhuis, CNAM ^a   Stegehuis, JH ^a   Walenkamp, AME ^a   de Jong, S ^a   de Vries, EGE ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 655; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CS 1008; CYTOTOXIC AGENT; DEATH RECEPTOR; DEATH RECEPTOR 4 ANTIBODY; DEATH RECEPTOR 5 ANTIBODY; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; LEXATUMUMAB; MAPATUMUMAB; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEMETREXED; RECOMBINANT DEATH RECEPTOR; RECOMBINANT PROTEIN; RITUXIMAB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BINDING AFFINITY; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHONDROSARCOMA; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; IMMUNOSURVEILLANCE; LIGAND BINDING; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; SOFT TISSUE SARCOMA; SURVIVAL RATE; SURVIVAL TIME; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; BRAIN NEOPLASMS; GLIOMA; HLA-DR4 ANTIGEN; HLA-DR5 ANTIGEN; HUMANS; NEOPLASMS; PYRAZINES; RECEPTORS, DEATH DOMAIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 51449118394     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.06.011     Document Type: Review

References (32)

1. Hymowitz S.G., O'Connell M.P., Ultsch M.H., Hurst A., Totpal K., Ashkenazi A., de Vos A.M., and Kelley R.F. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39 (2000) 633-640
2. Malhi H., and Gores G.J. TRAIL resistance results in cancer progression: a TRAIL to perdition?. Oncogene 25 (2006) 7333-7335
3. Hoffmann O., Priller J., Prozorovski T., Schulze-Topphoff U., Baeva N., Lunemann J.D., Aktas O., Mahrhofer C., Stricker S., Zipp F., et al. TRAIL limits excessive host immune responses in bacterial meningitis. J Clin Invest 117 (2007) 2004-2013
4. Zhu H., Dong H., Eksioglu E., Hemming A., Cao M., Crawford J.M., Nelson D.R., and Liu C. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology 133 (2007) 1649-1659
5. Rus V., Nguyen V., Puliaev R., Puliaeva I., Zernetkina V., Luzina I., Papadimitriou J.C., and Via C.S. T cell TRAIL promotes murine lupus by sustaining effector CD4 Th cell numbers and by inhibiting CD8 CTL activity. J Immunol 178 (2007) 3962-3972
6. Duiker E.W., Mom C.H., de Jong S., Willemse P.H., Gietema J.A., van der Zee A.G., and de Vries E.G. The clinical trail of TRAIL. Eur J Cancer 42 (2006) 2233-2240
7. Finnberg N., Klein-Szanto A.J., and El-Deiry W.S. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 118 (2008) 111-123
8. Grosse-Wilde A., Voloshanenko O., Bailey S.L., Longton G.M., Schaefer U., Csernok A.I., Schutz G., Greiner E.F., Kemp C.J., and Walczak H. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 118 (2008) 100-110. The authors generated TRAIL-receptor deficient mice and subsequently initiated skin tumors. The number, rate of development, and malignant transformation rate of benign papilloma did not differ between TRAIL-R-/- mice compared to TRAIL-R+/- and TRAIL-R+/+ mice. However TRAIL-R-/- mice developed earlier and significant more lymph node metastases, suggesting a protective role for the TRAIL-R in mice.
9. Trauzold A., Siegmund D., Schniewind B., Sipos B., Egberts J., Zorenkov D., Emme D., Roder C., Kalthoff H., and Wajant H. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25 (2006) 7434-7439. In this paper, the authors inoculated SCID mice with human pancreatic cancer cells overexpressing Bcl-XL, thereby inhibiting TRAIL-induced apoptosis. Upon rhTRAIL treatment a 5.8-fold increase in the tumor volume and a significant increase in the number of liver metastases were found compared to saline-treated mice.
10. Belyanskaya L.L., Ziogas A., Hopkins-Donaldson S., Kurtz S., Simon H.U., Stahel R., and Zangemeister-Wittke U. TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung Cancer 60 (2008) 355-365
11. Kelley S.K., Harris L.A., Xie D., Deforge L., Totpal K., Bussiere J., and Fox J.A. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299 (2001) 31-38
12. Marini P., Denzinger S., Schiller D., Kauder S., Welz S., Humphreys R., Daniel P.T., Jendrossek V., Budach W., and Belka C. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25 (2006) 5145-5154
13. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., Lee D., von Goetz M., Yee S.F., Totpal K., et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 13 (2007) 1070-1077
14. Carlo-Stella C., Lavazza C., Locatelli A., Vigano L., Gianni A.M., and Gianni L. Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res 13 (2007) 2313-2317
15. Van Geelen C.M., Westra J.L., de Vries E.G., Boersma-van E.W., Zwart N., Hollema H., Boezen H.M., Mulder N.H., Plukker J.T., de Jong S., et al. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 24 (2006) 4998-5004
16. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
17. Lefranc F., Brotchi J., and Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23 (2005) 2411-2422
18. Hao C., Beguinot F., Condorelli G., Trencia A., Van Meir E.G., Yong V.W., Parney I.F., Roa W.H., and Petruk K.C. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res 61 (2001) 1162-1170
19. Wohlfahrt M.E., Beard B.C., Lieber A., and Kiem H.P. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res 67 (2007) 8783-8790
20. Lee K.C., Hamstra D.A., Bhojani M.S., Khan A.P., Ross B.D., and Rehemtulla A. Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin Cancer Res 13 (2007) 1839-1846
21. Saito R., Bringas J.R., Panner A., Tamas M., Pieper R.O., Berger M.S., and Bankiewicz K.S. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res 64 (2004) 6858-6862
22. S to the death-inducing signaling complex and contributes to TRAIL resistance in human glioma. Cancer Res 67 (2007) 9482-9489. The authors show that high levels of the antiapoptotic protein FLIP alone are not sufficient enough to inhibit apoptosis. HSP90α is needed to serve as chaperone protein by recruiting FLIP to the DISC and inhibiting apoptosis in human glioma cells.
23. Yin D., Ong J.M., Hu J., Desmond J.C., Kawamata N., Konda B.M., Black K.L., and Koeffler H.P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 13 (2007) 1045-1052
24. Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets 8 (2008) 132-140
25. Koschny R., Holland H., Sykora J., Haas T.L., Sprick M.R., Ganten T.M., Krupp W., Bauer M., Ahnert P., Meixensberger J., et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 13 (2007) 3403-3412
26. Koschny R., Ganten T.M., Sykora J., Haas T.L., Sprick M.R., Kolb A., Stremmel W., and Walczak H. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 45 (2007) 649-658
27. Liu X., Yue P., Chen S., Hu L., Lonial S., Khuri F.R., and Sun S.Y. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 67 (2007) 4981-4988
28. Voortman J., Resende T.P., Abou El Hassan M.A., Giaccone G., and Kruyt F.A. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 6 (2007) 2103-2112
29. Smith M.R., Jin F., and Joshi I. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. Clin Cancer Res 13 (2007) 5528s-5534s
30. Tolcher A.W., Mita M., Meropol N.J., von Mehren M., Patnaik A., Padavic K., Hill M., Mays T., McCoy T., Fox N.L., et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25 (2007) 1390-1395. A phase 1 dose escalation study was performed with a fully human monoclonal antibody targeting DR4. Initially, patients received a single dose. After the confirmation of safety, dose and frequency of administration were carefully increased to 10 mg/kg every 14 days. Most common and mild adverse events were fatigue, fever, and myalgia. The authors showed that this antibody could be administered safely up to 10 mg/kg i.v. every two weeks.
31. Greco F.A., Bonomi P., Crawford J., Kelly K., Oh Y., Halpern W., Lo L., Gallant G., and Klein J. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61 (2008) 82-90
32. Plummer R., Attard G., Pacey S., Li L., Razak A., Perrett R., Barrett M., Judson I., Kaye S., Fox N.L., et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 13 (2007) 6187-6194